•  
  •  
  •  
 

RNA Leaders

We focus on developing novel RNA-centered approaches to addressing unmet medical needs. SomaGenics' research and development has been supported by over $20M in competitive grants and it is our policy to publish the results of our efforts in respected peer-reviewed journals. Our staff includes internationally recognized leaders in RNA research and technology development. Learn more...

more about SomaGenics

Latest from SomaGenics

 

SomaGenics awarded NIH funding to develop novel cell-free-DNA liquid biopsy platform

Santa Cruz, CA, May 2017- SomaGenics announced the receipt of a Phase I SBIR grant from the National Human Genome Research Institute to support extension of its RealSeq® platform to...

Read more

SomaGenics Presents RNAi Therapeutic Program

Santa Cruz, CA, May, 2017 – SomaGenics’ President and CEO, Brian Johnston, Ph.D., recently presented an invited seminar, “Treating chronic diabetic wounds: A small RNA approach,” to the Institute for...

Read more

SomaGenics presented research progress at the Symposium on Advanced Wound Care and Wound Healing Society

Santa Cruz, CA, April 2017 – SomaGenics presented recent progress in its wound healing therapeutic program at the joint meeting of the Symposium on Advanced Wound Care and the Wound...

Read more

SomaGenics Granted New Patents for RNA Detection and RNA-based Therapeutics Technologies

SANTA CRUZ, CA. November 2016 – SomaGenics, an RNA-focused biotechnology company, announced expansion of its intellectual property portfolio with issue of two new patents for its RNA analysis technologies (miR-ID®...

Read more

SomaGenics is a privately held biotech company with offices and laboratories located in Santa Cruz, CA. We specialize in small RNA technologies, including innovative RNAi-based therapeutics using sshRNA molecules, and diagnostics/biomarker detection of small or fragmented RNA, including microRNAs.

learn more